Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.

@article{Neoh2013EconomicEO,
  title={Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.},
  author={Chin Fen Neoh and Danny Liew and Monica A. Slavin and Dedre Marriott and Sharon C. A. Chen and Orla Morrissey and Kyana Stewart and David C. M. Kong},
  journal={Internal medicine journal},
  year={2013},
  volume={43 6},
  pages={668-77}
}
BACKGROUND Micafungin demonstrated non-inferiority to caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in a major randomised clinical trial. AIM The aim of this study was to investigate if micafungin is a cost-saving option compared with caspofungin for treating candidaemia and IC. METHODS A decision analytical model was constructed to capture downstream consequences of using either agent as initial therapy for candidaemia and IC. The main outcomes were… CONTINUE READING